Table 6.
Sensitivity analyses comparing IJV versus SCV
| Outcomes | OR (95 % CI) | |||
|---|---|---|---|---|
| Base casea | Using fixed-effects model | RCTs includeda | Non-randomized cohort studies includeda | |
| TIVAD-related infections | 0.71 (0.48–1.04) | 0.70 (0.47–1.03) | 0.47 (0.17–1.28) | 0.76 (0.50–1.16) |
| Catheter-related thrombotic complications | 0.76 (0.38–1.51) | 0.91 (0.57–1.43) | 0.90 (0.17–4.68) | 0.56 (0.27–1.16) |
| Total major mechanical complications | 0.38 (0.24–0.61) | 0.36 (0.26–0.49) | 0.30 (0.17–0.53) | 0.44 (0.22–0.88) |
| Catheter dislocation | 0.43 (0.22–0.84) | 0.43 (0.23–0.83) | NAb | 0.40 (0.15–1.07) |
| Malfunction | 0.42 (0.28–0.62) | 0.42 (0.28–0.62) | 0.28 (0.12–0.64) | 0.47 (0.30–0.74) |
| Catheter fracture | 0.47 (0.21–1.05) | 0.38 (0.18–0.78) | NAb | 0.50 (0.15–1.61) |
Abbreviation: NA not applicable
aRandom-effects model was used in these analyses
bSensitivity analysis was not conducted because only one study was included